Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 300

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome

Open access
Burn, John, Bishop, D. Timothy, Mecklin, Jukka-Pekka, Macrae, Finlay, Möslein, Gabriela, Olschwang, Sylviane, Bisgaard, Marie-Luise, Ramesar, Raj, Eccles, Diana, Maher, Eamonn R., Bertario, Lucio, Jarvinen, Heikki J., Lindblom, Annika, Evans, D. Gareth, Lubinski, Jan, Morrison, Patrick J., Ho, Judy W.C., Vasen, Hans F.A., Side, Lucy, Thomas, Huw J.W., Scott, Rodney J., Dunlop, Malcolm, Barker, Gail, Elliott, Faye, Jass, Jeremy R., Fodde, Ricardo, Lynch, Henry T., Mathers, John C.·2008·New England Journal of Medicine

Abstract

BACKGROUND: Observational and epidemiologic data indicate that the use of aspirin reduces the risk of colorectal neoplasia; however, the effects of aspirin in the Lynch syndrome (hereditary nonpolyposis colon cancer) are not known. Resistant starch has been associated with an antineoplastic effect on the colon. METHODS: In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome. RESULTS: Among 1071 persons in 43 centers, 62 were ineligible to participate in the study, 72 did not enter the study, and 191 withdrew from the study. These three categories were equally distributed across the study groups. Over a mean period of 29 months (range, 7 to 74), colonic adenoma or carcinoma developed in 141 participants. Of 693 participants randomly assigned to receive aspirin or placebo, neoplasia developed in 66 participants receiving aspirin (18.9%), as compared with 65 receiving placebo (19.0%) (relative risk, 1.0; 95% confidence interval [CI], 0.7 to 1.4). There were no significant differences between the two groups with respect to the development of advanced neoplasia (7.4% and 9.9%, respectively; P=0.33). Among the 727 participants receiving resistant starch or placebo, neoplasia developed in 67 participants receiving starch (18.7%), as compared with 68 receiving placebo (18.4%) (relative risk, 1.0; 95% CI, 0.7 to 1.4). Advanced adenomas and colorectal cancers were evenly distributed in the two groups. The prevalence of serious adverse events was low, and the events were evenly distributed. CONCLUSIONS: The use of aspirin, resistant starch, or both for up to 4 years has no effect on the incidence of colorectal adenoma or carcinoma among carriers of the Lynch syndrome. (Current Controlled Trials number, ISRCTN59521990.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0801297

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 300

Metadata

Authors
Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Möslein, G., Olschwang, S., Bisgaard, M.-L., Ramesar, R., Eccles, D., Maher, E. R., Bertario, L., Jarvinen, H. J., Lindblom, A., Evans, D. G., Lubinski, J., Morrison, P. J., Ho, J. W. C., Vasen, H. F. A., Side, L., Thomas, H. J. W., Scott, R. J., Dunlop, M., Barker, G., Elliott, F., Jass, J. R., Fodde, R., Lynch, H. T., & Mathers, J. C.
Venue
New England Journal of Medicine
Published
2008-12-11
Volume
359
Issue
24
Pages
2567-2578
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1997799520
Cited by
300
References
22
FWCI
11.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. https://app.cochat.ai/papers/10.1056/nejmoa0801297
The paper
Burn, J., Bishop, D. T., Mecklin, J.-P., Macrae, F., Möslein, G., Olschwang, S., Bisgaard, M.-L., Ramesar, R., Eccles, D., Maher, E. R., Bertario, L., Jarvinen, H. J., Lindblom, A., Evans, D. G., Lubinski, J., Morrison, P. J., Ho, J. W. C., Vasen, H. F. A., Side, L., . . . Mathers, J. C. (2008). Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome. New England Journal of Medicine. https://doi.org/10.1056/nejmoa0801297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.